Insmed, Inc. $INSM Shares Bought by UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC

Key Points

• UBS Asset Management increased its stake in Insmed, Inc. by 10.8%, now owning approximately $41.16 million worth of shares, totaling 539,484 shares.
• Several brokerages have upgraded Insmed's stock rating, with price targets raised significantly, including Wells Fargo increasing their target from $140 to $171.
• Insmed's latest earnings report showed a revenue increase of 18.9% year-over-year, while the company reported a higher-than-expected loss of $1.70 EPS.

UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in shares of Insmed, Inc. (NASDAQ:INSM - Free Report) by 10.8% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 539,484 shares of the biopharmaceutical company's stock after buying an additional 52,637 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC owned 0.30% of Insmed worth $41,157,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently bought and sold shares of INSM. Cetera Investment Advisers increased its position in shares of Insmed by 15.0% during the fourth quarter. Cetera Investment Advisers now owns 10,154 shares of the biopharmaceutical company's stock worth $701,000 after purchasing an additional 1,321 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Insmed by 10.9% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 105,313 shares of the biopharmaceutical company's stock worth $7,270,000 after purchasing an additional 10,352 shares in the last quarter. Nuveen Asset Management LLC increased its position in shares of Insmed by 19.4% during the fourth quarter. Nuveen Asset Management LLC now owns 1,266,630 shares of the biopharmaceutical company's stock worth $87,448,000 after purchasing an additional 205,473 shares in the last quarter. ProShare Advisors LLC increased its position in shares of Insmed by 43.0% during the fourth quarter. ProShare Advisors LLC now owns 56,991 shares of the biopharmaceutical company's stock worth $3,935,000 after purchasing an additional 17,141 shares in the last quarter. Finally, Snowden Capital Advisors LLC increased its position in shares of Insmed by 2.5% during the fourth quarter. Snowden Capital Advisors LLC now owns 6,602 shares of the biopharmaceutical company's stock worth $456,000 after purchasing an additional 158 shares in the last quarter.

Insmed Stock Performance

Shares of NASDAQ INSM traded down $1.10 during trading on Friday, reaching $144.76. 5,624,066 shares of the company traded hands, compared to its average volume of 1,971,056. Insmed, Inc. has a 12-month low of $60.40 and a 12-month high of $149.08. The company has a current ratio of 6.68, a quick ratio of 6.33 and a debt-to-equity ratio of 0.45. The stock has a market cap of $30.60 billion, a P/E ratio of -25.35 and a beta of 0.97. The firm's fifty day simple moving average is $124.17 and its 200 day simple moving average is $94.19.

Insmed (NASDAQ:INSM - Get Free Report) last posted its earnings results on Thursday, August 7th. The biopharmaceutical company reported ($1.70) EPS for the quarter, missing analysts' consensus estimates of ($1.30) by ($0.40). Insmed had a negative net margin of 259.82% and a negative return on equity of 195.37%. The business had revenue of $107.42 million for the quarter, compared to analyst estimates of $104.06 million. During the same quarter last year, the business earned ($1.94) earnings per share. Insmed's revenue was up 18.9% on a year-over-year basis. Insmed has set its FY 2025 guidance at EPS. As a group, research analysts anticipate that Insmed, Inc. will post -4.56 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Orlov S. Nicole Schaeffer sold 76,520 shares of the firm's stock in a transaction dated Friday, September 12th. The stock was sold at an average price of $145.45, for a total transaction of $11,129,834.00. Following the sale, the insider directly owned 36,461 shares in the company, valued at $5,303,252.45. This trade represents a 67.73% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Melvin Md Sharoky sold 10,000 shares of the firm's stock in a transaction dated Friday, September 12th. The shares were sold at an average price of $145.39, for a total value of $1,453,900.00. Following the sale, the director owned 262,675 shares in the company, valued at $38,190,318.25. This trade represents a 3.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 335,097 shares of company stock worth $39,721,648. 3.00% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on INSM shares. Wells Fargo & Company upped their price target on Insmed from $140.00 to $171.00 and gave the stock an "overweight" rating in a research report on Wednesday, September 3rd. Truist Financial upped their price target on Insmed from $126.00 to $139.00 and gave the stock a "buy" rating in a research report on Thursday, August 14th. The Goldman Sachs Group upped their price target on Insmed from $114.00 to $142.00 and gave the stock a "buy" rating in a research report on Wednesday, August 13th. Royal Bank Of Canada upped their target price on Insmed from $108.00 to $120.00 and gave the company an "outperform" rating in a research report on Friday, August 8th. Finally, Leerink Partners raised their target price on Insmed from $100.00 to $115.00 and gave the stock an "outperform" rating in a research note on Tuesday, June 10th. Sixteen analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, Insmed presently has an average rating of "Moderate Buy" and an average price target of $139.86.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.